RESOURCES

Home Resources Resource Center

Podcast Episode 23: Timur Kabadayı on Patient Safety, Product Quality, and Supply Chain Data Integrity



Key Takeaways

- The most important aspect of **The Agile Supply Chain Credo** is its focus on patient safety and meeting patient demand right time, first time, every time.
- Companies across the end-to-end pharma supply chain produce and deliver medicines—but they also create data that can be shared to improve demand forecasts and boost supply chain agility.
- The global pharma industry could potentially save billions of dollars through digital supply chain enhancements—money which could then be reinvested in research and development.

×

Pharma companies are increasingly taking an end-to-end view of the supply chain so they can ultimately deliver the right patient outcomes. Data is a critical component that enables you to achieve this goal by enabling you to manage the



product on its journey to the patient, according to Timur Kabadayı, Managing Director of Conval Group, an information technology consulting firm that specializes in the life sciences industry. In this episode of The Agile Supply Chain Podcast, Kabadayı explains how the right approach to data management can help pharma companies and supply chain teams improve product safety and quality.

Return to: Agile Supply Chain Insights

PodcastSupply Chain CollaborationSupply Chain Subscribe to Agile Supply Chain Insights Stay informed with the latest patient-centric agile supply chain thought leadership content. SUBSCRIBE Subscribe to Agile Supply Chain Insights Stay informed with the latest patient-centric agile supply chain thought leadership content.

Related Content





Podcast Episode 20: HFS Research on The Agile Supply Chain Credo and the New Era of Supply Chain Transformation

Learn about The Agile Supply Chain Credo and get expert advice on how to carry our your supply chain transformation.

View More



Sink or Swim? IDC Survey Reveals Who Will Win in the Age of Pharma Supply Chain Disruption

Find out who will be the leaders—and who will be the laggards—in the era of increasing pharma supply chain disruptions.

View More